Subscribe to our Newsletters !!
Try to recall a splendid snorkelling or diving adv
The blending of delicate biological specimens in m
This doesn't feel like another one of my English e
It is with utmost pride that Microbioz India annou
Alembic Pharmaceutica
For some time now,
In our cover story, we shine a spotlight on “ The Magazine
Inhalation Sciences AB today announces that the company has received two new orders for a total value of EUR 27,400. The orders come from returning customers who have chosen to re-order IRS (Inhalation Research Services) studies via ISAB’s advanced exposure platforms PreciseInhale® and DissolvIt® for ongoing preclinical inhalation studies.
In recent weeks, ISAB has received several requests and these two formal orders reinforce the picture of a growing need for accurate and regulatory relevant data in inhalation research.
A key driver behind this development is the recent announcement by the U.S. Food and Drug Administration (FDA) of new guidelines and initiatives to reduce and eventually replace animal studies in drug development. In this change, reliable in vitro methods play a central role.
ISAB’s platforms are specifically designed to meet these new regulatory needs, including enabling controlled particle exposure, realistic lung imaging and simulations of lung dissolution dynamics. This provides customers with robust data that both supports internal development and facilitates regulatory communication.
“We see a clear trend: regulatory authorities are increasingly demanding alternative test methods with high physiological relevance,” says Manoush Masarrat, CEO of Inhalation Sciences. “The fact that returning customers are choosing PreciseInhale® and DissolvIt® in new projects shows that our technology is well positioned for a new era in drug development — where animal-free, predictive models are a crucial part of regulatory approval.”
